Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

Phase 2

Terminated

Conditions: Bleeding During/Following Surgery
Acquired Bleeding Disorder

Interventions: Drug: standard therapy
Drug: activated recombinant human factor VII
Drug: placebo

First Posted Date: 2012-03-28

Last Posted Date: 2017-02-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 11

Registration Number: NCT01564563

Locations: 🇺🇸
Novo Nordisk Investigational Site, Houston, Texas, United States

Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis

Phase 1

Completed

Conditions: Inflammation
Rheumatoid Arthritis

Interventions: Drug: placebo
Drug: NNC0114-0006

First Posted Date: 2012-03-28

Last Posted Date: 2017-02-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 32

Registration Number: NCT01565408

Locations: 🇷🇺
Novo Nordisk Investigational Site, Yaroslavl, Russian Federation

Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A With Inhibitors
Healthy
Haemophilia B With Inhibitors

Interventions: Drug: activated recombinant human factor VII
Drug: placebo

First Posted Date: 2012-03-27

Last Posted Date: 2017-01-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 39

Registration Number: NCT01563471

Locations: 🇫🇷
Novo Nordisk Investigational Site, Paris, France

Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients

Phase 2

Completed

Conditions: Trauma
Acquired Bleeding Disorder

Interventions: Drug: placebo
Drug: activated recombinant human factor VII

First Posted Date: 2012-03-27

Last Posted Date: 2017-01-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 283

Registration Number: NCT01563523

Locations: 🇬🇧
Novo Nordisk Investigational Site, Birmingham, United Kingdom

Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation

Phase 2

Completed

Conditions: Acquired Bleeding Disorder
Bleeding During/Following Surgery

Interventions: Drug: activated recombinant human factor VII
Drug: placebo

First Posted Date: 2012-03-27

Last Posted Date: 2017-01-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 208

Registration Number: NCT01563458

Locations: 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom

Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency

Phase 3

Completed

Conditions: Turner Syndrome
Growth Hormone Disorder
Growth Hormone Deficiency in Children
Genetic Disorder

Interventions: Drug: somatropin

First Posted Date: 2012-03-27

Last Posted Date: 2017-02-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 168

Registration Number: NCT01563926

Locations: 🇮🇱
Novo Nordisk Investigational Site, Tel - Aviv, Israel

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

Phase 2

Completed

Conditions: Acquired Bleeding Disorder
Intracerebral Haemorrhage

Interventions: Drug: placebo
Drug: activated recombinant human factor VII

First Posted Date: 2012-03-27

Last Posted Date: 2017-01-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 40

Registration Number: NCT01563445

Locations: 🇺🇸
Novo Nordisk Investigational Site, New York, New York, United States

Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: repaglinide
Drug: insulin NPH

First Posted Date: 2012-03-26

Last Posted Date: 2017-02-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 213

Registration Number: NCT01562561

Locations: 🇨🇳
Novo Nordisk Investigational Site, Tainan city, Taiwan

Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A
Haemophilia B

Interventions: Drug: activated recombinant human factor VII

First Posted Date: 2012-03-26

Last Posted Date: 2017-01-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 18

Registration Number: NCT01562587

Locations: 🇬🇧
Novo Nordisk Investigational Site, Oxford, United Kingdom

Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients

Phase 4

Completed

Conditions: Growth Hormone Disorder
Adult Growth Hormone Deficiency

Interventions: Drug: placebo
Drug: somatropin

First Posted Date: 2012-03-26

Last Posted Date: 2024-02-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 22

Registration Number: NCT01562834

Locations: 🇫🇷
Novo Nordisk Investigational Site, Vandoeuvre Les Nancy, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy